US FDA approves Ultragenyx gene therapy for rare fatal disease
FDA approved Ultragenyx's NASDAQ:RARE gene therapy for treatment of a rare, fatal disease.
Story updates
06:45:49 PM UTC
SquawkNews
The U.S FDA said on Thursday it has approved Ultragenyx's NASDAQ:RARE gene therapy for the treatment of a rare, fatal disease.The approval makes Fayuvi the first therapy for Sanfilippo syndrome Type A, caused by a missing enzyme that stops the body from breaking down a complex sugar molecule called…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.